The Oncology Institute, Inc. (TOIIW) 股票分析

公司概述

The Oncology Institute, Inc. operates as an oncology provider in the United States, delivering a comprehensive suite of services through three distinct segments: specialty pharmacy, patient services, and clinical trials and other operations. Although specific sector and industry classifications are not disclosed in the available data, the company's business model focuses on physician services, in-house infusion, and in-house specialty pharmacy within the healthcare landscape. The company employs a workforce of 641 individuals to support its operational footprint. While the market capitalization is not currently listed in the provided financial records, the annual revenue stands at $502.73 million, indicating a substantial operational scale relative to the specialized oncology market. These revenue figures, combined with the significant employee count, suggest that the company has established a notable presence in the oncology services space, despite the lack of explicit market cap data to quantify its total equity value in the current trading environment.

财务健康

The company reported trailing twelve-month revenue of $502.73 million, yet it recorded a net income loss of $-50,305,000, revealing a substantial gap between top-line growth and profitability that points to a cost structure dominated by high operating expenses or significant one-time charges. The entity also generated an EBITDA of $-29,139,000, further highlighting the challenges in converting revenue into operating cash earnings. Free cash flow for the period was $-11,004,375, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations solely from internal cash generation without external capital injections. Margin analysis shows a gross margin of 15.2%, suggesting moderate efficiency in direct cost management, while the operating margin sits at -4.9% and the profit margin is negative at -12.1%, reflecting significant overhead burdens relative to revenue. On the balance sheet, the company holds $33.56 million in cash against total debt of $103.75 million, creating a net debt position, though a specific debt-to-equity ratio is not disclosed in the available facts. The current ratio is 1.59, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, maintaining a conservative stance on immediate liquidity requirements. Additionally, the return on equity is not available for calculation, while the return on assets stands at -13.4%, signaling that management is currently generating negative returns on the asset base employed in the business.

估值评估

Trailing P/E, forward P/E, and price-to-sales ratios are not available in the provided data, preventing a direct comparison of earnings trajectory or sales-based valuation multiples. The price-to-book ratio is recorded at -0.37, a negative metric that typically arises in biotechnology or growth-oriented firms with intangible-heavy balance sheets or significant accumulated deficits, indicating that the market prices the equity at a discount relative to its book value. Since price-to-sales and EV/EBITDA multiples are not disclosed, alternative valuation metrics are unavailable to assess the company's relative value against peers. Over the past year, the stock traded between a 52-week high of $0.06 and a 52-week low of $0.03, with the current price position relative to this range dependent on the real-time market price not specified in the static data. The stock exhibits a beta of 0.20, which suggests that its price volatility is significantly lower than the broader market, implying that the stock price is less sensitive to general market fluctuations compared to the S&P 500 index.

Growth & Income

Revenue growth for the trailing twelve-month period is reported at 41.6% year-over-year, demonstrating robust expansion in top-line sales, while earnings growth is not applicable due to the company's net losses. Because the company is not generating positive net income, it does not pay dividends, meaning there is no dividend yield or payout ratio to evaluate for sustainability. Consequently, the company does not distribute earnings to shareholders but instead reinvests its capital and any available cash reserves into expanding its oncology service offerings and clinical trial operations. The overall growth and income profile is characterized by strong revenue acceleration in the absence of current profitability, indicating a growth-stage business model where capital deployment is prioritized over immediate shareholder returns through dividends.